$KTTA
Pasithea Therapeutics Corp. Stock $ktta

$ktta Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000121390022072281 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$240.7K	$218.6K	$0.00
YoY Change	1498.34%
Cost Of Revenue	-$1.310K	$86.47K
YoY Change	-107.58%
Gross Profit	$242.0K	$132.1K
YoY Change	-11001.8%
Gross Profit Margin	100.54%	60.45%
Selling, General & Admin	$3.936M	$3.224M	$1.274M
YoY Change	101.45%	153.14%
% of Gross Profit	1626.47%	2439.75%
Research & Development	$1.387M	$1.159M
YoY Change
% of Gross Profit	572.89%	877.08%
Depreciation & Amortization	-$100.00	$16.67K
YoY Change	-107.25%
% of Gross Profit	-0.04%	12.62%
Operating Expenses	$5.323M	$4.383M	$1.274M
YoY Change	172.4%	244.14%
Operating Profit	-$5.081M	-$4.251M	-$1.274M
YoY Change	159.72%	233.76%
Interest Expense	$980.4K	-$335.3K	-$252.5K
YoY Change	-62.09%	32.79%
% of Operating Profit
Other Income/Expense, Net	-$280.00	-$335.3K	-$252.5K
YoY Change	1300.0%	32.79%
Pretax Income	-$5.118M	-$4.586M	-$1.526M
YoY Change	-912.18%	200.51%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$5.118M	-$4.586M	-$1.526M
YoY Change	-912.18%	200.51%
Net Earnings / Revenue	-2126.08%	-2097.88%
Basic Earnings Per Share		-$0.17	-$0.17
Diluted Earnings Per Share	-$0.18	-$0.17	-$116.9K
COMMON SHARES
Basic Shares Outstanding	29.25M shares	26.70M shares	8.956M shares
Diluted Shares Outstanding		26.55M shares	8.956M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$33.15M	$42.40M	$20.57M
YoY Change	-37.42%	106.16%
Cash & Equivalents	$33.15M	$42.40M	$20.57M
Short-Term Investments
Other Short-Term Assets	$302.1K	$866.0K	$468.5K
YoY Change		84.83%
Inventory
Prepaid Expenses	$627.7K	$1.205M
Receivables
Other Receivables
Total Short-Term Assets	$34.08M	$44.47M	$21.03M
YoY Change	-36.07%	111.42%
LONG-TERM ASSETS
Property, Plant & Equipment	$378.8K	$340.5K	$8.570K
YoY Change	1782.25%	3873.3%
Goodwill	$1.263M	$3.854M
YoY Change
Intangibles	$8.587M	$12.50K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$11.10M	$5.139M	$8.570K
YoY Change	55074.9%	59863.97%
TOTAL ASSETS
Total Short-Term Assets	$34.08M	$44.47M	$21.03M
Total Long-Term Assets	$11.10M	$5.139M	$8.570K
Total Assets	$45.18M	$49.61M	$21.04M
YoY Change	-15.27%	135.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.614M	$1.256M	$528.1K
YoY Change	260.92%	137.82%
Accrued Expenses	$263.3K	$258.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.878M	$1.514M	$528.1K
YoY Change	319.79%	186.68%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$804.2K	$1.306M	$4.039M
YoY Change	-44.64%	-67.68%
Total Long-Term Liabilities	$804.2K	$1.306M	$4.039M
YoY Change	-44.64%	-67.68%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.878M	$1.514M	$528.1K
Total Long-Term Liabilities	$804.2K	$1.306M	$4.039M
Total Liabilities	$2.682M	$2.819M	$4.567M
YoY Change	41.14%	-38.27%
SHAREHOLDERS EQUITY
Retained Earnings	-$19.36M	-$11.03M
YoY Change	774.1%
Common Stock	$17.99K	$18.04K
YoY Change	1.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares	2.700M shares
Shareholders Equity	$42.50M	$46.79M	$16.48M
YoY Change
Total Liabilities & Shareholders Equity	$45.18M	$49.61M	$21.04M
YoY Change	-15.27%	135.75%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$5.118M	-$4.586M	-$1.526M
YoY Change	-912.18%	200.51%
Depreciation, Depletion And Amortization	-$100.00	$16.67K
YoY Change	-107.25%
Cash From Operating Activities	-$4.419M	-$5.239M	-$548.5K
YoY Change	153.32%	855.19%
INVESTING ACTIVITIES
Capital Expenditures	$1.789M	-$197.4K	-$8.570K
YoY Change	-13935.96%	2203.85%
Acquisitions
YoY Change
Other Investing Activities	$32.98K	-$32.98K
YoY Change
Cash From Investing Activities	-$1.756M	-$230.4K	-$8.570K
YoY Change	13480.82%	2588.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-3.206M	0.000	20.55M
YoY Change	-109.38%	-100.0%
NET CHANGE
Cash From Operating Activities	-4.419M	-5.239M	-548.5K
Cash From Investing Activities	-1.756M	-230.4K	-8.570K
Cash From Financing Activities	-3.206M	0.000	20.55M
Net Change In Cash	-9.381M	-5.469M	20.00M
YoY Change	-128.95%	-127.35%
FREE CASH FLOW
Cash From Operating Activities	-$4.419M	-$5.239M	-$548.5K
Capital Expenditures	$1.789M	-$197.4K	-$8.570K
Free Cash Flow	-$6.208M	-$5.041M	-$539.9K
YoY Change	258.54%	833.78%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8442395	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8956197	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	005-92867
	dei	Entity Registrant Name EntityRegistrantName	PASITHEA THERAPEUTICS CORP.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1591963
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1111 Lincoln Road
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 500
	dei	Entity Address City Or Town EntityAddressCityOrTown	Miami Beach
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33139
	dei	City Area Code CityAreaCode	(702)
	dei	Local Phone Number LocalPhoneNumber	514-4174
	dei	Security12b Title Security12bTitle	Common stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	KTTA
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	29248688	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42398233	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52966706	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1205174	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	333751	usd
CY2022Q3	us-gaap	Other Assets Current OtherAssetsCurrent	865985	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	44469392	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	340512	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20124	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	931964	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	53300457	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	12502	usd
CY2022Q3	us-gaap	Goodwill Goodwill	3853934	usd
CY2022Q3	us-gaap	Assets Assets	49608304	usd
CY2021Q4	us-gaap	Assets Assets	53320581	usd
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1255951	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	447280	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	258031	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1513982	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	447280	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	724386	usd
CY2022Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	581120	usd
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	1452800	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1305506	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1452800	usd
CY2022Q3	us-gaap	Liabilities Liabilities	2819488	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1900080	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	495000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	495000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26548688	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26548688	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23008371	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23008371	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	18038	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	17684	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	57950620	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	53627883	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-146573	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-10561	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-11033269	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2214505	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	46788816	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	51420501	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	49608304	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53320581	usd
CY2022Q3	us-gaap	Revenues Revenues	218608	usd
	us-gaap	Revenues Revenues	245847	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	86465	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	114503	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	132143	usd
	us-gaap	Gross Profit GrossProfit	131344	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3223955	usd
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1273600	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8587866	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2551156	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1159001	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1278922	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4250813	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1273600	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9735444	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2551156	usd
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	335317	usd
CY2021Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	252508	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-871680	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	252508	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	45000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-335317	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-252508	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	916680	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-252508	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4586130	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1526108	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8818764	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2803664	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4586130	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1526108	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8818764	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2803664	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26548688	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8956197	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24415888	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8442395	shares
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4586130	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1526108	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8818764	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2803664	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-82514	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1450	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-136012	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3762	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4668644	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1527558	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8954776	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2807426	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	241355	usd
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1208926	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-549609	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	900672	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	299665	usd
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	-2312	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-727947	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	470078	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	15000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	750000	usd
CY2021Q3	ktta	Sale Of Units SaleOfUnits	4800000	shares
CY2021Q3	ktta	Stock Issued During Period Value Netof Underwriting Discountsand Offering Costs StockIssuedDuringPeriodValueNetofUnderwritingDiscountsandOfferingCosts	20554800	usd
CY2021Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4800000	shares
CY2021Q3	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	3600000	usd
CY2021Q3	ktta	Issuance Of Representatives Warrants IssuanceOfRepresentativesWarrants	240000	shares
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	187200	usd
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	-1450	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1526108	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	16475120	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	51420501	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	135630	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	-4513	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1574240	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	49977378	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	125392	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	282241	usd
CY2022Q2	ktta	Stock Issued During Period Value Warrants Instrument Issued For Acquisition StockIssuedDuringPeriodValueWarrantsInstrumentIssuedForAcquisition	350722	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	3293479	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	-48985	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2658394	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	51321833	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	135627	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	-82514	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4586130	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	46788816	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8818764	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2803664	usd
	us-gaap	Depreciation Depreciation	32471	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	396649	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	314665	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	282241	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	750000	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-871680	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	252000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	822043	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	464219	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	865985	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	506428	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	521493	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	17453	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10143230	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1429725	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	349624	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8570	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-44078	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-305546	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8570	usd
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	21862200	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1208926	usd
	ktta	Payment Of Offering Costs PaymentOfOfferingCosts	-1307400	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21763726	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-119697	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-3762	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10568473	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	20321669	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52966706	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	243650	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42398233	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20565319	usd
	ktta	Lease Liabilities Arising From Obtaining Rightofuse Assets LeaseLiabilitiesArisingFromObtainingRightofuseAssets	931964	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use of Estimates</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these condensed consolidated financial statements is the determination of fair value of the warrant liabilities. Accordingly, the actual results could differ significantly from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	374182	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	21503	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	33670	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1379	usd
CY2022Q3	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	16670	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	32471	usd
CY2021Q3	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	0	usd
	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	0	usd
CY2021Q3	ktta	Offering Costs OfferingCosts	3445200	usd
CY2021Q3	us-gaap	Expense Related To Distribution Or Servicing And Underwriting Fees ExpenseRelatedToDistributionOrServicingAndUnderwritingFees	2137800	usd
CY2021Q3	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	1307400	usd
CY2022Q3	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Concentration of Credit Risk</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. As of September 30, 2022, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
	ktta	Payments In Advance PaymentsInAdvance	1	pure
CY2022Q3	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.30	pure
CY2022Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.0001
CY2022Q3	us-gaap	Foreign Currency Exchange Rate Remeasurement1 ForeignCurrencyExchangeRateRemeasurement1	1.117	pure
CY2021Q4	us-gaap	Foreign Currency Exchange Rate Remeasurement1 ForeignCurrencyExchangeRateRemeasurement1	1.348	pure
CY2022Q3	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	1.257	pure
CY2021Q4	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	1.371	pure
CY2022Q3	ktta	Foreign Currency Exchange Rate Remeasurements ForeignCurrencyExchangeRateRemeasurements	0.98	pure
CY2021Q4	ktta	Foreign Currency Exchange Rate Remeasurements ForeignCurrencyExchangeRateRemeasurements	1.132	pure
CY2022Q3	ktta	Foreign Currency Exchange Rate Translation ForeignCurrencyExchangeRateTranslation	1.062	pure
CY2021Q4	ktta	Foreign Currency Exchange Rate Translation ForeignCurrencyExchangeRateTranslation	1.143	pure
	us-gaap	Class Of Warrant Or Right Expense Or Revenue Recognized ClassOfWarrantOrRightExpenseOrRevenueRecognized	Each Unit consisted of one share of Common Stock and one Public Warrant. Each redeemable Public Warrant entitles the holder to purchase one share of Common Stock at a price of $6.25 per share, will be exercisable upon issuance and will expire five years from issuance.
CY2022Q2	us-gaap	Lessee Finance Lease Description LesseeFinanceLeaseDescription	The lease has a 60-month term, and the Company has an option to extend the term for one 5-year renewal period at the prevailing market rate that the landlord is then obtaining from tenants for comparable space in the building. The lease has a base monthly rent of $8,336 per month for the first 12 months, with the base monthly rent increasing by 4% on the first anniversary of the lease commencement date and every 12 months thereafter. In addition to the base monthly rent, commencing on the first anniversary of the lease commencement date, the Company will pay its share of certain direct operating and tax expenses incurred by the landlord in maintaining the building.
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	431000	usd
CY2022Q3	us-gaap	General Fair Value Hedge Information Minimum R Square Percentage GeneralFairValueHedgeInformationMinimumRSquarePercentage	0.078	pure
CY2022Q4	us-gaap	Sale Leaseback Transaction Monthly Rental Payments SaleLeasebackTransactionMonthlyRentalPayments	15700	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	568972	usd
CY2022Q3	us-gaap	Interest Rate Derivative Assets At Fair Value InterestRateDerivativeAssetsAtFairValue	7.8	usd
CY2022Q3	us-gaap	Excess Stock Shares Authorized ExcessStockSharesAuthorized	500000000	shares
	ktta	Description Of Authorized Capital Stock DescriptionOfAuthorizedCapitalStock	The authorized capital stock is divided into: (i) 495,000,000 shares of common stock having a par value of $0.0001 per share and (ii) 5,000,000 shares of preferred stock having a par value of $0.0001 per share.
CY2021	us-gaap	Payments For Repurchase Of Private Placement PaymentsForRepurchaseOfPrivatePlacement	1000000	usd
CY2021	ktta	Sale Of Stock Number Of Shares Issued In Transaction1 SaleOfStockNumberOfSharesIssuedInTransaction1	625000	shares
CY2021Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.6
	ktta	Shares Issued1 SharesIssued1	395625	shares
	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	633000	usd
CY2021Q4	ktta	Cash Fee CashFee	0.09	pure
CY2021Q4	ktta	Accountable Expenses AccountableExpenses	70000	usd
CY2022Q2	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	3260870	shares
CY2022Q2	us-gaap	Financial Instrument Subject To Mandatory Redemption Par Value Per Share FinancialInstrumentSubjectToMandatoryRedemptionParValuePerShare	1.01
CY2021Q4	ktta	Shares Per Shares SharesPerShares	8680000	shares
CY2021Q4	ktta	Purchase To Warrants PurchaseToWarrants	8680000	shares
CY2021Q4	ktta	Offering Price Per OfferingPricePer	3.5
CY2021Q4	ktta	Aggregate Gross Proceeds AggregateGrossProceeds	30380000	usd
CY2021Q4	ktta	Underwriter Discounts And Fees UnderwriterDiscountsAndFees	27000000	usd
	ktta	Warrants Remain Outstanding WarrantsRemainOutstanding	8680000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	600000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.81
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	400000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1000000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.68
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	250000	shares
	ktta	Weightedaverage Exercise Price Per Share Exercisable WeightedaverageExercisePricePerShareExercisable	5
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P9Y2M19D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	0	usd
CY2022Q3	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	100000	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	300000	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	30000.00	usd
CY2022Q3	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	400000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.45
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate	0.404	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.032	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y6M
	ktta	Additionalpaidin Capital And Compensation Expenses AdditionalpaidinCapitalAndCompensationExpenses	151500	usd
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	1120000	shares
CY2021Q4	ktta	Exercised Price Per Share ExercisedPricePerShare	6.25
CY2021Q4	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	7000000	usd
	ktta	Fair Value Of Public Warrants FairValueOfPublicWarrants	0.148
	ktta	Fair Value Of Representative Warrants FairValueOfRepresentativeWarrants	0.152
CY2022Q2	us-gaap	Reinsurance Retention Policy Reinsured Risk Percentage ReinsuranceRetentionPolicyReinsuredRiskPercentage	1	pure
CY2022Q2	us-gaap	Class Of Warrant Or Right Unissued ClassOfWarrantOrRightUnissued	1000000	shares
CY2022Q2	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	1.88
CY2022Q2	us-gaap	Average Term Of Credit Risk Derivatives1 AverageTermOfCreditRiskDerivatives1	P5Y
CY2022Q2	us-gaap	Additional Collateral Aggregate Fair Value AdditionalCollateralAggregateFairValue	400000	usd
CY2022Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	77060	usd
CY2022Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets	49380	usd
CY2022Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets	19551	usd
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	3833453	usd
CY2022Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	3979444	usd
CY2022Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	335243	usd
CY2022Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities	335243	usd
CY2022Q3	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	3644201	usd
	us-gaap	Acquisition Costs AcquisitionCosts	311065	usd
CY2021Q4	us-gaap	Goodwill Goodwill		usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q3	us-gaap	Revenues Revenues		usd
	us-gaap	Revenues Revenues		usd
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold		usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold		usd
CY2021Q3	us-gaap	Gross Profit GrossProfit		usd
	us-gaap	Gross Profit GrossProfit		usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24415888	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26548688	shares
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2021Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2022Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices		usd
	us-gaap	Depreciation Depreciation		usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities		usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	ktta	Payment Of Offering Costs PaymentOfOfferingCosts		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
	ktta	Lease Liabilities Arising From Obtaining Rightofuse Assets LeaseLiabilitiesArisingFromObtainingRightofuseAssets		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
	ktta	Weightedaverage Exercise Price Per Share Expired WeightedaverageExercisePricePerShareExpired
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001841330

Files In Submission

Name	View Source	Status
0001213900-22-072281-index-headers.html	Edgar Link	pending
0001213900-22-072281-index.html	Edgar Link	pending
0001213900-22-072281.txt	Edgar Link	pending
0001213900-22-072281-xbrl.zip	Edgar Link	pending
f10q0922ex10-1_pasithea.htm	Edgar Link	pending
f10q0922ex31-1_pasithea.htm	Edgar Link	pending
f10q0922ex31-2_pasithea.htm	Edgar Link	pending
f10q0922ex32-1_pasithea.htm	Edgar Link	pending
f10q0922_pasitheatherap.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ktta-20220930.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ktta-20220930_cal.xml	Edgar Link	unprocessable
ktta-20220930_def.xml	Edgar Link	unprocessable
ktta-20220930_lab.xml	Edgar Link	unprocessable
ktta-20220930_pre.xml	Edgar Link	unprocessable
f10q0922_pasitheatherap_htm.xml	Edgar Link	completed
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KTTA
Pasithea Therapeutics Corp. Stock $ktta

2022 Q4 Form 10-Q Financial Statement

#000121390022072281 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KTTA Pasithea Therapeutics Corp. Stock $ktta

2022 Q4 Form 10-Q Financial Statement

#000121390022072281 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KTTA
Pasithea Therapeutics Corp. Stock $ktta